Detailed information for compound 974917

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 379.452 | Formula: C22H25N3O3
  • H donors: 2 H acceptors: 2 LogP: 5.23 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(Nc1noc(c1)C(C)(C)C)Nc1ccc(c(c1C)C)Oc1ccccc1
  • InChi: 1S/C22H25N3O3/c1-14-15(2)18(27-16-9-7-6-8-10-16)12-11-17(14)23-21(26)24-20-13-19(28-25-20)22(3,4)5/h6-13H,1-5H3,(H2,23,24,25,26)
  • InChiKey: PQKMOJLRNGNVBB-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens Raf-1 proto-oncogene, serine/threonine kinase Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Loa Loa (eye worm) TKL/RAF/RAF protein kinase Get druggable targets OG5_130459 All targets in OG5_130459
Schistosoma mansoni serine/threonine protein kinase Get druggable targets OG5_130459 All targets in OG5_130459
Loa Loa (eye worm) raf kinase Get druggable targets OG5_130459 All targets in OG5_130459
Schistosoma japonicum ko:K04365 B-Raf proto-oncogene serine/threonine-protein kinase, putative Get druggable targets OG5_130459 All targets in OG5_130459
Echinococcus granulosus raf serine:threonine protein kinase Get druggable targets OG5_130459 All targets in OG5_130459
Brugia malayi Raf kinase Get druggable targets OG5_130459 All targets in OG5_130459
Echinococcus multilocularis raf serine:threonine protein kinase Get druggable targets OG5_130459 All targets in OG5_130459

By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Echinococcus multilocularis glutamate receptor, ionotrophic, AMPA 3 0.0257 0.606 0.5659
Loa Loa (eye worm) glutamate receptor 1 0.021 0.3427 0.5467
Treponema pallidum amino acid ABC transporter, periplasmic binding protein 0.0235 0.4864 0.5
Mycobacterium tuberculosis Probable glutamine-binding lipoprotein GlnH (GLNBP) 0.0235 0.4864 0.5
Chlamydia trachomatis arginine ABC transporter substrate-binding protein ArtJ 0.0235 0.4864 0.5
Loa Loa (eye worm) glutamate receptor 2 0.021 0.3427 0.5467
Echinococcus multilocularis Glutamate receptor, ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus granulosus Glutamate receptor ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus granulosus glutamate receptor 2 0.0257 0.606 0.5659
Schistosoma mansoni serine/threonine protein kinase 0.0262 0.6339 1
Echinococcus multilocularis Glutamate receptor, ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus multilocularis glutamate (NMDA) receptor subunit 0.021 0.3427 0.2758
Treponema pallidum amino acid ABC transporter, periplasmic binding protein (hisJ) 0.0235 0.4864 0.5
Echinococcus granulosus raf serine:threonine protein kinase 0.0262 0.6339 0.5967
Echinococcus granulosus glutamate receptor ionotrophic AMPA 3 0.0257 0.606 0.5659
Mycobacterium ulcerans glutamine-binding lipoprotein GlnH 0.0235 0.4864 0.5
Loa Loa (eye worm) raf kinase 0.026 0.6268 1
Echinococcus granulosus Glutamate receptor ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus multilocularis Glutamate receptor, ionotropic kainate 3 0.0327 1 1
Echinococcus multilocularis raf serine:threonine protein kinase 0.0262 0.6339 0.5967
Chlamydia trachomatis glutamine binding protein 0.0235 0.4864 0.5
Echinococcus multilocularis glutamate receptor 2 0.021 0.3427 0.2758
Echinococcus granulosus glutamate NMDA receptor subunit 0.021 0.3427 0.2758
Echinococcus multilocularis nmda type glutamate receptor 0.0327 1 1
Echinococcus multilocularis Glutamate receptor, ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus granulosus Glutamate receptor ionotropic kainate 2 0.0257 0.606 0.5659
Echinococcus multilocularis glutamate receptor 2 0.0257 0.606 0.5659
Brugia malayi Raf kinase 0.0253 0.5829 1
Schistosoma mansoni glutamate receptor NMDA 0.0257 0.606 0.904

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 650 nM Inhibition of Raf-1 ChEMBL. 18947905

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.